Download MendeleyQuinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss, C.J., Cooper, A.W., Eldred, C.D., Kranz, M., Lindvall, M., Lucas, F.S., Neu, M., Preston, A.G., Ranshaw, L.E., Redgrave, A.J., Ed Robinson, J., Shipley, T.J., Solanke, Y.E., Somers, D.O., Wiseman, J.O.(2009) Bioorg Med Chem Lett 19: 1380-1385
- PubMed: 19195882
- DOI: https://doi.org/10.1016/j.bmcl.2009.01.045
- Primary Citation of Related Structures:
3FRG - PubMed Abstract:
Crystallography-driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of a series of quinoline derivatives that were highly potent and selective inhibitors of PDE4 with a good pharmacokinetic profile in the rat. Quinolines 43 and 48 have potential as oral medicines for the treatment of COPD.
Organizational Affiliation:
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, England.
